Biotechnology Industry
Filter News
Found 24,540 articles
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
BioSpace Movers & Shakers, June 18
6/18/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
In the report to the Committee on the Judiciary in the U.S. Senate, the GAO says drug makers have spent nearly $8.2 billion on DTC drug ads in three therapeutic areas from 2016 to 2018.
-
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
6/18/2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products Administration
-
Reven Pharmaceuticals Reports a Promising Second Generation Formulation of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX)
6/18/2021
Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Biomedicine and Pharmacotherapy .
-
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
6/18/2021
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16 th Annual International Conference on Malignant Lymphoma
-
Moderna Reaffirms Commitment to Job Creation in Massachusetts
6/18/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reaffirmed its commitment to job creation in Massachusetts.
-
Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
6/18/2021
IVERIC bio, Inc. announced that at the Company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2, the Company’s pivotal clinical trial of Zimura® in development for the treatment of geographic atrophy secondary to age-related macular degeneration.
-
Bioelectronica® Corporation Wins Annual CYTO Virtual Interactive 2021 Innovation Showcase
6/18/2021
Bioelectronica ® Corporation announced today that the company won the Innovation Showcase competition that was held at CYTO Virtual Interactive 2021.
-
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
6/18/2021
Aditx Therapeutics, Inc. announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
-
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
6/18/2021
Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round.
-
Codex DNA Announces Pricing of Initial Public Offering
6/18/2021
Codex DNA, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, announced the pricing of its initial public offering of 6,666,665 shares of its common stock at a public offering price of $16.00 per share.
-
AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds
6/18/2021
AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, announced that it has been granted its first disease treatment patent by the United States Patent and Trademark Office on June 7, 2021.
-
deCODE genetics: Predicting the probability of death
6/18/2021
Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.
-
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
6/18/2021
BioNTech SE, announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial.
-
Nordic Nanovector ASA: Increase of share capital - June 18, 2021
6/18/2021
The two US-based board members of Nordic Nanovector ASA, Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 22,860 RSUs that were issued to them in June 2020 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2020 to the annual general meeting in 2021 in RSUs.
-
Cybin to Present at the Emerging Growth Conference on June 23rd
6/18/2021
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Emerging Growth Conference on June 23, 2021.
-
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
-
The new findings likely throw a wrench in the company's plans to deliver millions of much-needed vaccine doses to the European Union soon.
-
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.